权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Genetic variant-based drug discovery targeting conserved pathways of aging

针对保守的衰老途径的基于遗传变异的药物发现

基本信息

批准号：
9359668
负责人：
JAN VIJG
金额：
$ 191.07万
依托单位：
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-15 至 2022-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9359668
关键词：
Affect Aging Animal Model Apoptosis Biological Assay Cardiovascular Diseases Cell Aging Cell Culture System Cells Centenarian Clinical Code Collaborations Computer Simulation Development Disease Drug Targeting Elderly FDA approved FRAP1 gene FVB Mouse Family history of Foundations Gene Expression Gene Targeting Genes Genetic Genetic Variation Genetically Engineered Mouse Genome engineering Genomic Instability Genotype Health Human Human Engineering Human Genetics Hybrids I Kappa B-Alpha IGF1 gene Individual Intervention Link Longevity Longevity Pathway Malignant Neoplasms Medicine MicroRNAs Modeling Molecular Mus Mutagens Natural Products Nature Nerve Degeneration Non-Insulin-Dependent Diabetes Mellitus Nucleic Acid Regulatory Sequences Outcome Pathologic Pathway interactions Pharmaceutical Preparations Pharmacologic Substance Pharmacology Phenotype Physiological Processes Plague Population Regulation Research Research Project Grants Resources Risk Factors Signal Transduction Symptoms Testing Therapeutic Untranslated RNA Variant age related aged base college drug discovery efficacy testing exome experimental study follower of religion Jewish genetic resource genetic variant healthy aging human disease middle age mouse model mutant novel novel strategies novel therapeutics prevent rare variant response screening small molecule small molecule inhibitor therapeutic development therapy development tool ward whole genome

项目摘要

ABSTRACT - OVERALL Aging is an important risk factor for most common human diseases, including type 2 diabetes, cardiovascular disease, cancer and neurodegeneration. In the proposed collaborative U19 proposal, we will test a new approach for developing therapies for these diseases. Rather than focusing on individual diseases, we will explore genetic differences between successfully aged, healthy centenarians and control individuals with no family history of extreme longevity. Based on our own preliminary results, many of such genetic differences affect loci known to be involved in extreme longevity and health span in model organisms, such as worms and mice. Using the centenarian resource at the Albert Einstein College of Medicine, we will identify rare genetic variants and microRNAs associated with conserved mechanisms of healthy longevity as potential targets, for drug discovery (Project 1), evaluate these variants or associated pathways functionally in mouse models of aging, including natural aging, for phenotypes relevant for late-life human health (Project 2), and subsequently use them as leads for developing and testing small molecules targeting the pathways affected by these rare variants and miRNAs (Project 3). This integrated research project will be supported by two cores: an Administrative Core to coordinate the research (Core A) and a Genetically Engineered Mouse and Geropathology Core (Core B). Using our extensive genetic resources, including some from our pharmaceutical partner, Regeneron, we also will confirm further and validate some of the genetic variants and discover additional, novel genetic variants and associated pathways important for human longevity. The proposed project should greatly increase our understanding of the importance of the conserved pro-longevity pathways, identified and thus far mostly studied in model organisms, for human aging. Importantly, this gene to drugs collaborative project will be the first to use the genetics of rare individuals with healthy aging as a guide for the development of therapeutic approaches for targeting aging itself rather than its composite diseases for preventing, delaying onset and progression, and possibly even reverting many multiple age-related diseases.

摘要-总体